Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Free Cash Flow (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Free Cash Flow for 16 consecutive years, with -$979523.0 as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 7.13% to -$979523.0 in Q4 2025 year-over-year; TTM through Oct 2025 was -$4.5 million, a 133.41% decrease, with the full-year FY2025 number at -$3.0 million, down 38.43% from a year prior.
  • Free Cash Flow was -$979523.0 for Q4 2025 at PharmaCyte Biotech, up from -$2.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $342959.0 in Q3 2023 to a low of -$2.0 million in Q3 2025.
  • A 5-year average of -$877187.2 and a median of -$959913.0 in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 131.63% in 2023, then crashed 434.15% in 2025.
  • PharmaCyte Biotech's Free Cash Flow stood at -$1.4 million in 2021, then crashed by 35.63% to -$1.9 million in 2022, then decreased by 5.59% to -$2.0 million in 2023, then surged by 46.85% to -$1.1 million in 2024, then grew by 7.13% to -$979523.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Free Cash Flow are -$979523.0 (Q4 2025), -$2.0 million (Q3 2025), and -$1.0 million (Q2 2025).